Published in Cardiovasc Toxicol on January 01, 2007
Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst (2009) 2.55
Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol (2008) 2.04
Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. Antioxid Redox Signal (2012) 1.37
Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. Circulation (2012) 1.14
Adverse effects of treatment in childhood acute lymphoblastic leukemia: general overview and implications for long-term cardiac health. Expert Rev Hematol (2011) 1.07
National Cancer Institute-National Heart, Lung and Blood Institute/pediatric Blood and Marrow Transplant Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: long-term organ damage and dysfunction. Biol Blood Marrow Transplant (2011) 1.01
Cardiotoxicity of the new cancer therapeutics--mechanisms of, and approaches to, the problem. Drug Discov Today (2008) 0.97
Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation. Br J Haematol (2013) 0.96
Long-term consequences of hematopoietic stem cell transplantation: current state of the science. Biol Blood Marrow Transplant (2009) 0.87
Chronic health conditions in childhood cancer survivors: is it all treatment-related--or do genetics play a role? J Gen Intern Med (2009) 0.87
Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivors. Cancer Epidemiol Biomarkers Prev (2011) 0.87
Cardiovascular effects in childhood cancer survivors treated with anthracyclines. Cardiol Res Pract (2011) 0.86
Cardiac side effects of anticancer treatments: new mechanistic insights. Curr Heart Fail Rep (2012) 0.86
Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage. Curr Hypertens Rep (2010) 0.83
Unexpected doxorubicin-mediated cardiotoxicity in sisters: possible role of polymorphisms in histamine n-methyl transferase. J Oncol Pharm Pract (2012) 0.81
Role of DNA Methylation on the Expression of the Anthracycline Metabolizing Enzyme AKR7A2 in Human Heart. Cardiovasc Toxicol (2016) 0.80
The Crossroads of Geriatric Cardiology and Cardio-Oncology. Curr Geriatr Rep (2015) 0.78
Imaging of early modification in cardiomyopathy: the doxorubicin-induced model. Int J Cardiovasc Imaging (2013) 0.77
Mitochondrionopathy phenotype in doxorubicin-treated Wistar rats depends on treatment protocol and is cardiac-specific. PLoS One (2012) 0.77
Correlation of aldo-ketoreductase (AKR) 1C3 genetic variant with doxorubicin pharmacodynamics in Asian breast cancer patients. Br J Clin Pharmacol (2013) 0.76
Current Views on Anthracycline Cardiotoxicity in Childhood Cancer Survivors. Pediatr Cardiol (2015) 0.76
Long-term follow-up for cardiovascular disease after chemotherapy and/or radiotherapy for breast cancer in an unselected population. Support Care Cancer (2014) 0.76
The anthracyclines: when good things go bad. Cardiovasc Toxicol (2007) 0.75
GSEA-SNP: applying gene set enrichment analysis to SNP data from genome-wide association studies. Bioinformatics (2008) 2.52
Genome-wide single-nucleotide polymorphism arrays demonstrate high fidelity of multiple displacement-based whole-genome amplification. Electrophoresis (2005) 1.45
Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos (2002) 1.40
Antitumor effects of a combined 5-aza-2'deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice. Cancer Res (2009) 1.30
B-Raf acts via the ROCKII/LIMK/cofilin pathway to maintain actin stress fibers in fibroblasts. Mol Cell Biol (2004) 1.28
Three haplotypes associated with CYP2A6 phenotypes in Caucasians. Pharmacogenet Genomics (2005) 1.26
The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). J Biol Chem (2004) 1.16
Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem (2005) 1.14
Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. Drug Metab Dispos (2008) 1.14
Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine. J Biol Chem (2002) 1.10
ALDH-2 deficiency increases cardiovascular oxidative stress--evidence for indirect antioxidative properties. Biochem Biophys Res Commun (2007) 1.09
Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes. Pharmacogenomics (2007) 1.07
Gp91phox-containing NAD(P)H oxidase increases superoxide formation by doxorubicin and NADPH. Free Radic Biol Med (2006) 1.06
Time-point and dosage of gene inactivation determine the tumor spectrum in conditional Ptch knockouts. Carcinogenesis (2009) 1.03
A model for PTCH1/Ptch1-associated tumors comprising mutational inactivation and gene silencing. Int J Oncol (2005) 0.98
Dominant contribution of P450 3A4 to the hepatic carcinogenic activation of aflatoxin B1. Chem Res Toxicol (2006) 0.98
Topoisomerase II{alpha}-dependent and -independent apoptotic effects of dexrazoxane and doxorubicin. Mol Cancer Ther (2009) 0.92
A critical function for B-Raf at multiple stages of myelopoiesis. Blood (2005) 0.92
Cytochrome P450 3A and their regulation. Naunyn Schmiedebergs Arch Pharmacol (2003) 0.90
B-Raf-mediated signaling pathway regulates T cell development. Eur J Immunol (2008) 0.89
Inactivation of Patched1 in mice leads to development of gastrointestinal stromal-like tumors that express Pdgfrα but not kit. Gastroenterology (2012) 0.89
6-mercaptopurine and 9-(2-phosphonyl-methoxyethyl) adenine (PMEA) transport altered by two missense mutations in the drug transporter gene ABCC4. Hum Mutat (2008) 0.89
Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics. Pharmacogenet Genomics (2006) 0.88
Nitric oxide production and endothelium-dependent vasorelaxation ameliorated by N1-methylnicotinamide in human blood vessels. Hypertension (2012) 0.87
PI3K inhibition enhances doxorubicin-induced apoptosis in sarcoma cells. PLoS One (2012) 0.87
Differential roles of nitric oxide synthase isozymes in cardiotoxicity and mortality following chronic doxorubicin treatment in mice. Naunyn Schmiedebergs Arch Pharmacol (2009) 0.86
A functional polymorphism in the NAD(P)H oxidase subunit CYBA is related to gene expression, enzyme activity, and outcome in non-Hodgkin lymphoma. Cancer Res (2010) 0.86
CYP3 phylogenomics: evidence for positive selection of CYP3A4 and CYP3A7. Pharmacogenet Genomics (2008) 0.85
Evolutionary history and functional characterization of the amphibian xenosensor CAR. Mol Endocrinol (2011) 0.84
Re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst (2002) 0.82
[Chemotherapeutics-induced heart failure]. Med Klin (Munich) (2007) 0.82
Variability in PXR-mediated induction of CYP3A4 by commercial preparations and dry extracts of St. John's wort. Naunyn Schmiedebergs Arch Pharmacol (2007) 0.81
Lineage-specific duplications of Muroidea Faim and Spag6 genes and atypical accelerated evolution of the parental Spag6 gene. J Mol Evol (2013) 0.80
Dystrophin-deficiency increases the susceptibility to doxorubicin-induced cardiotoxicity. Eur J Heart Fail (2007) 0.80
Contribution of nitric oxide synthase isoforms to cholinergic vasodilation in murine retinal arterioles. Exp Eye Res (2013) 0.80
Functional characterization of protein variants of the human multidrug transporter ABCC2 by a novel targeted expression system in fibrosarcoma cells. Hum Mutat (2012) 0.80
Pharmacogenomics of diuretic drugs: data on rare monogenic disorders and on polymorphisms and requirements for further research. Pharmacogenomics (2003) 0.79
Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms. BMC Cancer (2014) 0.78
Limited contribution of CYP3A5 to the hepatic 6beta-hydroxylation of testosterone. Naunyn Schmiedebergs Arch Pharmacol (2004) 0.78
The unique complexity of the CYP3A4 upstream region suggests a nongenetic explanation of its expression variability. Pharmacogenet Genomics (2010) 0.77
Topoisomerase II beta expression level correlates with doxorubicin-induced apoptosis in peripheral blood cells. Naunyn Schmiedebergs Arch Pharmacol (2006) 0.77
Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20(+) B-cell lymphoma. Pharmacogenomics (2015) 0.77
Ligand diversity of human and chimpanzee CYP3A4: activation of human CYP3A4 by lithocholic acid results from positive selection. Drug Metab Dispos (2009) 0.77
Application of genomewide SNP arrays for detection of simulated susceptibility loci. Hum Mutat (2005) 0.77
The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells. Br J Pharmacol (2015) 0.77
Correction: Structural and Functional Similarity of Amphibian Constitutive Androstane Receptor with Mammalian Pregnane X Receptor. PLoS One (2016) 0.75
Pregnane X receptor and yin yang 1 contribute to the differential tissue expression and induction of CYP3A5 and CYP3A4. PLoS One (2012) 0.75
ADHD drugs and cardiovascular risk. N Engl J Med (2006) 0.75